Log in

NASDAQ:IOVA - Iovance Biotherapeutics Stock Price, Forecast & News

$22.01
+0.37 (+1.71 %)
(As of 01/29/2020 06:00 AM ET)
Today's Range
$21.67
Now: $22.01
$22.09
50-Day Range
$21.64
MA: $25.99
$29.41
52-Week Range
$8.31
Now: $22.01
$29.67
Volume641,567 shs
Average Volume1.30 million shs
Market Capitalization$2.78 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IOVA
CUSIPN/A
Phone650-260-7120

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.78 per share

Profitability

Net Income$-123,580,000.00

Miscellaneous

Employees88
Market Cap$2.78 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.


Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics Inc (NASDAQ:IOVA) posted its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.01. View Iovance Biotherapeutics' Earnings History.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Iovance Biotherapeutics.

What price target have analysts set for IOVA?

12 analysts have issued 12-month price targets for Iovance Biotherapeutics' shares. Their forecasts range from $27.00 to $38.00. On average, they anticipate Iovance Biotherapeutics' share price to reach $31.73 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price. View Analyst Price Targets for Iovance Biotherapeutics.

What is the consensus analysts' recommendation for Iovance Biotherapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iovance Biotherapeutics.

What are Wall Street analysts saying about Iovance Biotherapeutics stock?

Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (1/14/2020)
  • 2. HC Wainwright analysts commented, "Our thesis on TILs stands strong. In accordance with our thesis, showing efficacy in solid tumors beyond melanoma continues to represent a game changer for Iovance and, on a broader look, we continue to view this company as a viable takeout candidate for Big Pharma. We would like to reiterate that, apart from academic-based TILs therapies such as NCI and MD Anderson, Iovance is the only biotech that is developing a commercial TIL product to treat a variety of tumors and patients using the predefined cryopreserved 22-day manufacturing strategy." (7/2/2019)
  • 3. Chardan Capital analysts commented, "We therefore expect to see a similar rate in the registration-directed Cohort 4 which is currently enrolling." (5/31/2019)

Has Iovance Biotherapeutics been receiving favorable news coverage?

News articles about IOVA stock have been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Iovance Biotherapeutics earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the near future. View News Stories for Iovance Biotherapeutics.

Are investors shorting Iovance Biotherapeutics?

Iovance Biotherapeutics saw a decline in short interest in January. As of January 15th, there was short interest totalling 14,830,000 shares, a decline of 9.5% from the December 31st total of 16,390,000 shares. Based on an average daily trading volume, of 1,270,000 shares, the short-interest ratio is currently 11.7 days. Approximately 12.8% of the shares of the stock are sold short. View Iovance Biotherapeutics' Current Options Chain.

Who are some of Iovance Biotherapeutics' key competitors?

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Portola Pharmaceuticals (PTLA), Applied Materials (AMAT), Immunomedics (IMMU), Kadmon (KDMN), BlackRock (BLK), CA (CA), Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY), Novavax (NVAX) and Heron Therapeutics (HRTX).

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the folowing people:
  • Dr. Maria Fardis, CEO, Pres & Director (Age 51)
  • Mr. Timothy E. Morris, CFO, Principal Accounting Officer, Corp. Sec. & Treasurer (Age 57)
  • Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 45)
  • Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 59)
  • Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 62)

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.43%), Rhenman & Partners Asset Management AB (0.38%), California Public Employees Retirement System (0.25%), Strs Ohio (0.10%), Moody Lynn & Lieberson LLC (0.06%) and Tocqueville Asset Management L.P. (0.05%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Institutional Ownership Trends for Iovance Biotherapeutics.

Which institutional investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Tocqueville Asset Management L.P., Rhenman & Partners Asset Management AB, Evanson Asset Management LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Iovance Biotherapeutics.

Which institutional investors are buying Iovance Biotherapeutics stock?

IOVA stock was purchased by a variety of institutional investors in the last quarter, including Moody Lynn & Lieberson LLC, Dupont Capital Management Corp, Virginia Retirement Systems ET AL, California Public Employees Retirement System, Intellectus Partners LLC, Strs Ohio and SG Americas Securities LLC. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Insider Buying and Selling for Iovance Biotherapeutics.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $22.01.

How big of a company is Iovance Biotherapeutics?

Iovance Biotherapeutics has a market capitalization of $2.78 billion. The biotechnology company earns $-123,580,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.View Additional Information About Iovance Biotherapeutics.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is http://www.iovance.com/.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]


MarketBeat Community Rating for Iovance Biotherapeutics (NASDAQ IOVA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  441 (Vote Outperform)
Underperform Votes:  248 (Vote Underperform)
Total Votes:  689
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/29/2020 by MarketBeat.com Staff

Featured Article: Monthly Dividend Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel